Kanada - enska - Health Canada

teva canada limited - octreotide (octreotide acetate) - powder for suspension, sustained-release - 20mg - octreotide (octreotide acetate) 20mg - miscellaneous therapeutic agents

Kanada - enska - Health Canada

teva canada limited - octreotide (octreotide acetate) - powder for suspension, sustained-release - 30mg - octreotide (octreotide acetate) 30mg - miscellaneous therapeutic agents

Kanada - enska - Health Canada

generic medical partners inc - octreotide (octreotide acetate) - solution - 50mcg - octreotide (octreotide acetate) 50mcg - miscellaneous therapeutic agents

Kanada - enska - Health Canada

generic medical partners inc - octreotide (octreotide acetate) - solution - 100mcg - octreotide (octreotide acetate) 100mcg - miscellaneous therapeutic agents

Kanada - enska - Health Canada

generic medical partners inc - octreotide (octreotide acetate) - solution - 500mcg - octreotide (octreotide acetate) 500mcg - miscellaneous therapeutic agents

Evrópusambandið - enska - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - acromegaly - pituitary and hypothalamic hormones and analogues - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Ísrael - enska - Ministry of Health

easy care ltd, israel - octreotide as acetate - solution for injection - octreotide as acetate 0.1 mg/ml - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreostat treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. octreostat is not an antitumour therapy and is not curative in these patients. emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Ísrael - enska - Ministry of Health

easy care ltd, israel - octreotide as acetate - solution for injection - octreotide as acetate 0.5 mg/ml - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreostat treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. octreostat is not an antitumour therapy and is not curative in these patients. emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Írland - enska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 100 microgram(s)/millilitre - somatostatin and analogues; octreotide

Írland - enska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 200 microgram(s)/millilitre - somatostatin and analogues; octreotide